ABBV vs NVO
AbbVie and Novo Nordisk A/S, both Healthcare
AbbVie is the larger company at $382B against $211B. Over the past year ABBV returned +27% against -35% for NVO. The RyuScore puts NVO ahead, 88 against 52 out of 100.
| Figure | ABBV | NVO |
|---|---|---|
| Last close | $276 | $38.62 |
| Market cap | $382B | $211B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 78.1 | n/a |
| Dividend yield | 2.4% | n/a |
| 1-year return | +27% | -35% |
| 5-year return | +207% | -15% |
| RyuScoresector-relative, 1–10 | 52/100 | 88/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
AbbVie
Revenue of $17B in Q2 2026, net income $3.6B. Its largest reported line is SKYRIZI, 36% of the disclosed total.
Novo Nordisk A/S
Open these two in the interactive comparison to add more names, change the period or see the correlation.